YOLFTbeta
VivoSim Labs, Inc.

VivoSim Labs, Inc.

VIVS · NASDAQ · Healthcare / Biotechnology

0.1271USD-0.01 (-7.83%)

Price History

Full chart

Market Stats

Previous Close0.1379
Open0.1376
Day Range0.125 – 0.1376
52-Week Range0.2155 – 3.54
Volume403.90K
Market Cap2.95M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.38
Dividend Yield0.00%
Beta1.45
50-Day Avg0.3162
200-Day Avg1.29

About

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Keith E. Murphy
  • Employees15
  • Headquarters11555 Sorrento Valley Road, San Diego, CA, United States, 92121, USA
  • Websitehttps://vivosim.ai

Leadership

  • Mr. Keith E. MurphyExecutive Chairman & Corporate Secretary · b. 1972
  • Mr. Norman StaskeyPresident, CFO & Principal Financial Officer · b. 1970
  • Dr. Amar A. Sethi M.D., Ph.D.Chief Scientific Officer · b. 1971
  • Mr. Tony LialinChief Commercial Officer · b. 1971

Financials

Income Statement

Currency: USD2011-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Revenue-1.20M379.00K571.00K1.48M4.23M4.60M3.09M2.20M01.50M370.00K109.00K144.00K131.00K
Growth (%)---68.34%+50.66%+159.72%+185.23%+8.82%-32.85%-28.96%-100.00%--75.33%-70.54%+32.11%-9.03%
Cost of Revenue-----956.00K1.03M482.00K328.00K0--05.00K0
Gross Profit-1.20M379.00K571.00K1.48M3.27M3.57M2.61M1.87M01.50M370.00K109.00K139.00K131.00K
Gross Margin-100.00%100.00%100.00%100.00%77.40%77.62%84.41%85.06%-100.00%100.00%100.00%96.53%100.00%
Operating Expense-10.52M21.03M30.87M40.13M41.85M38.84M29.88M23.34M16.83M12.98M18.10M15.20M12.76M11.36M
Operating Income--9.32M-20.65M-30.30M-38.64M-38.58M-35.27M-27.27M-21.48M-16.83M-11.48M-17.73M-15.09M-12.62M-11.22M
Operating Margin--778.53%-5448.28%-5305.95%-2605.73%-911.94%-766.26%-882.37%-977.91%--765.27%-4792.16%-13840.37%-8761.11%-8567.94%
EBITDA-117.82K-42.27M-25.45M-29.61M-37.83M-37.43M-34.00M-26.29M-20.33M-13.98M-11.30M-16.96M-14.39M-2.21M-13.57M
EBITDA Margin--3531.33%-6714.51%-5185.46%-2550.78%-884.78%-738.74%-850.66%-925.91%--753.60%-4584.86%-13200.92%-1534.72%-10355.73%
Net Income-147.82K-43.55M-25.85M-30.08M-38.58M-38.45M-34.80M-26.64M-18.71M-16.83M-11.45M-17.26M-14.67M-2.49M-13.84M
Net Income Margin--3638.51%-6820.05%-5268.30%-2601.15%-908.91%-756.09%-861.70%-852.00%--763.20%-4664.59%-13459.63%-1727.78%-10567.18%
R&D-3.44M7.97M12.92M18.01M19.55M17.96M14.75M5.28M1.10M3.32M8.88M5.50M5.03M4.19M
R&D as % of Total Revenue-287.05%2103.96%2262.87%1214.30%462.06%390.09%477.26%240.62%-221.33%2401.35%5044.04%3489.58%3197.71%
Interest Expense-1.09M13.00K1.00K--------010.00K12.00K
Interest Expense % of Total Revenue-90.89%3.43%0.18%--------0.00%6.94%9.16%

Balance Sheet

Currency: USD2011-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Total Assets4.28K16.75M50.19M53.49M67.58M69.18M49.83M40.62M28.44M39.92M33.30M20.31M6.35M14.65M7.39M
Total Liabilities10.69K22.05M1.90M4.79M5.39M6.82M5.24M4.33M1.81M721.00K3.09M4.98M2.75M4.16M8.48M
Total Equity-6.42K-5.30M48.28M48.70M62.18M62.36M44.59M36.30M26.63M39.20M30.21M15.33M3.60M10.49M-1.10M
Cash1.77K14.82M48.17M50.14M62.09M62.75M43.73M36.48M27.36M37.36M28.68M15.30M2.90M11.31M5.02M
Total Debt-27.00K15.00K5.00K------2.18M1.80M1.39M942.00K447.00K
Net Debt-1.77K-14.79M-48.15M-50.14M-62.09M-62.75M-43.73M-36.48M-27.36M-37.36M-26.49M-13.50M-1.51M-10.37M-4.58M

Cash Flow

Currency: USD2011-03-312013-03-312014-03-312015-03-312016-03-312017-03-312018-03-312019-03-312020-03-312021-03-312022-03-312023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow-109.42K-9.69M-15.56M-19.60M-29.37M-29.18M-28.86M-20.38M-14.88M-13.32M-8.45M-12.41M-14.65M-9.46M-10.83M
Investing Cash Flow-30.00K-445.00K-268.00K-1.52M-2.13M-1.39M-292.00K-76.00K747.00K-393.00K-409.00K-966.00K816.00K9.03M94.00K
Financing Cash Flow7524.61M48.37M23.09M43.45M31.25M10.11M13.15M4.93M23.84M205.00K01.44M8.85M4.45M
Capital Expenditure30.00K357.00K277.00K1.52M2.15M1.35M296.00K79.00K0405.00K409.00K396.00K42.00K13.00K0
Free Cash Flow-139.43K-10.05M-15.84M-21.12M-31.52M-30.54M-29.15M-20.45M-14.88M-13.73M-8.86M-12.80M-14.70M-9.47M-10.83M
FCF to OCF127.42%103.68%101.78%107.74%107.32%104.64%101.03%100.39%100.00%103.04%104.84%103.19%100.29%100.14%100.00%

Earnings

Report DateMar 31, 2012Jun 30, 2012Nov 14, 2012Dec 31, 2012Aug 9, 2013Nov 27, 2013Feb 7, 2014Jun 10, 2014Aug 12, 2014Nov 10, 2014Feb 9, 2015Jun 9, 2015Aug 10, 2015Nov 9, 2015Feb 8, 2016Jun 9, 2016Aug 4, 2016Nov 3, 2016Feb 9, 2017Jun 7, 2017Aug 9, 2017Nov 9, 2017Feb 8, 2018May 31, 2018Aug 9, 2018Nov 8, 2018Feb 7, 2019May 22, 2019Aug 8, 2019Nov 7, 2019Feb 11, 2020Jun 10, 2020Aug 6, 2020Nov 5, 2020Feb 9, 2021May 20, 2021Aug 5, 2021Nov 4, 2021Feb 8, 2022May 26, 2022Aug 11, 2022Nov 10, 2022Feb 9, 2023May 25, 2023Aug 10, 2023Nov 9, 2023Feb 8, 2024May 10, 2024Aug 5, 2024Nov 8, 2024Feb 19, 2025May 22, 2025Aug 12, 2025Nov 6, 2025Feb 27, 2026Jun 25, 2026Aug 12, 2026Nov 5, 2026
EPS Estimate--168.00--14.40--21.60-21.60--21.60-21.60-1.80-22.20-24.80-26.40-2.20-24.00-26.40-22.80-2.15-24.00-24.00-21.60-0.07-19.20-16.80-15.60-0.06-12.00-12.00-0.05-0.05-0.06-0.06-----------0.46-5.16-4.92-5.04-3.96-2.64-2.40-2.28-2.28-2.28----
EPS Actual-1.17-197.37166.08-53.20-14.40-34.28-16.80-19.20-19.73-26.40-21.60-0.10-24.00-28.80-26.40-0.09-21.60-24.00-21.60-0.10-22.56-21.60-16.80-0.07-15.98-12.00-14.40-275.41-12.00-11.42-7.20-0.02-0.02-1.36-1.36-0.37-0.34-0.29-0.40-0.22-0.37-0.38-0.37-10.27-5.52-5.52-4.80-8.04-2.76-1.68-2.284.21-1.14-0.98-1.03-2.21-0.25-
Surprise---1.14%-0.00%-22.22%11.11%--22.22%0.00%94.44%-8.11%-16.13%0.00%95.91%10.00%9.09%5.26%95.35%6.00%10.00%22.22%0.00%16.77%28.57%7.69%-458916.67%0.00%4.83%-14300.00%60.00%66.67%-2166.67%-----------1100.00%-6.98%2.44%-59.52%30.30%36.36%5.00%284.65%50.00%57.02%----
Timing--After-hours-After-hours-Pre-marketAfter-hours-Pre-marketPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours---------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-------

Key Statistics & Ratios

Market Cap2.95M
Enterprise Value1.72M
Trailing P/E0.00
Forward P/E0.00
Price / Sales26.33
Price / Book0.54
EPS-4.38
Book Value-0.734
Revenue (TTM)112.00K
Gross Profit (TTM)-4.21M
EBITDA-11.14M
Profit Margin0.00%
Operating Margin-15327.78%
Return on Equity-343.10%
Return on Assets-89.50%
Shares Outstanding13.39M
Shares Float14.42M
Beta1.45
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
11.09%
Insiders
2.67%
Retail / Other
86.24%

Top Institutional Holders

  • Geode Capital Management, LLC
    36.85K0.22%
  • The Goldman Sachs Group Inc
    16.07K0.10%
  • Vanguard Capital Management, LLC
    15.37K0.09%
  • BlackRock Inc
    11.82K0.07%
  • Vanguard Fiduciary Trust Co
    7.00K0.04%
  • Citigroup Inc
    6.50K0.04%
  • Tower Research Capital LLC
    2.31K0.01%
  • UBS Group AG
    9520.01%
  • SBI Securities Co Ltd
    2210.00%
  • Hanson Mcclain Inc
    2080.00%
  • Larson Financial Group, LLC
    1660.00%
  • Albion Financial Group (Utah)
    1590.00%
  • Wells Fargo & Co
    1110.00%
  • Advisor Group Holdings, Inc.
    950.00%
  • Morgan Stanley - Brokerage Accounts
    500.00%
  • Integrated Wealth Concepts LLC
    80.00%
  • Caitong International Asset Management Co., Limited.
    30.00%

Top Fund Holders

  • Fidelity Extended Market Index
    13.67K0.08%
  • Fidelity Series Total Market Index
    4.05K0.02%
  • Fidelity Total Market Index
    9910.01%

Stock Splits

  • Mar 21, 20251:12
  • Aug 19, 20201:20